Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1Lymphoid 1Endocrine 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Weight Gain 1Overweight 1Multiple Endocrine Neoplasia Type 1 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sucrose × Endocrine × Clear all
NCT04804397 2021-03-18

Effects of Sucrose Added Blind to the Diet Over Eight Weeks on Body Mass and Weight in Men

University of Hull

Phase NA Completed
80 enrolled
Endocrine

Weight Gain, Multiple Endocrine Neoplasia Type 1, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡